eGene is Seeking Partners for Its Business of DNA Samples Collection in Airport Terminals
hursday April 27, 12:40 pm ET
IRVINE, Calif.--(BUSINESS WIRE)--April 27, 2006--eGene Inc. (OTCBB:EGEI - News), a leading biotechnology company, announced that it is looking for global business partners in the DNA sample collection in airport terminals.
The company's leading product, the compact and automated digital genetic analyzer, HDA-GT12(TM), is already achieving rapid penetration and acceptance in the current genetic research and testing market. Acting CEO of eGene, Dr. Ming Liu, said, "The DNA samples collection combines both the informative and instrumental aspects of DNA analysis, which is an integral part of our business approach."
eGene was awarded a U.S. patent (6,645,718) titled, "DNA sample collection for identification." The patent describes a process of collecting DNA samples for identification purposes in the event of a cataclysmic accident. This is a new, low-cost way to benefit air travel passengers and their families.
For example, in the last decade, hundreds of plane crash victims have remained unidentified because of incomplete information. Dr. Liu believes that airline passengers can take advantage of the company's patented identification technology and process in combination with flight insurance purchases, or through the requirements of various airlines.
"Passengers can choose to temporarily store their DNA samples at an airport terminal for specific flights," Dr. Liu explained. "In the event of an accident, the stored samples can be sent to authorized DNA testing labs for faster personal identification. This benefits the victims' families, the airlines and the insurance companies by avoiding time-consuming and costly individual DNA identification work."
http://biz.yahoo.com/bw/060427/20060427005802.html?.v=1
DNA samples required to fly; Next on the TSA agenda?
